Prevantics Maxi Swabstick Patent Expiration

Prevantics Maxi Swabstick is a drug owned by Professional Disposables Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 14, 2021. Details of Prevantics Maxi Swabstick's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USD468424 Swabstick
Jan, 2017

(7 years ago)

Expired


FDA has granted several exclusivities to Prevantics Maxi Swabstick. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Prevantics Maxi Swabstick, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Prevantics Maxi Swabstick.

Exclusivity Information

Prevantics Maxi Swabstick holds 1 exclusivities. All of its exclusivities have expired in 2021. Details of Prevantics Maxi Swabstick's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
M(M-221) Feb 14, 2021

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Prevantics Maxi Swabstick is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prevantics Maxi Swabstick's family patents as well as insights into ongoing legal events on those patents.

Prevantics Maxi Swabstick's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Prevantics Maxi Swabstick's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 14, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Prevantics Maxi Swabstick Generics:

There are no approved generic versions for Prevantics Maxi Swabstick as of now.

Alternative Brands for Prevantics Maxi Swabstick

There are several other brand drugs using the same active ingredient (Chlorhexidine Gluconate; Isopropyl Alcohol) as Prevantics Maxi Swabstick. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.






About Prevantics Maxi Swabstick

Prevantics Maxi Swabstick is a drug owned by Professional Disposables Inc. Prevantics Maxi Swabstick uses Chlorhexidine Gluconate; Isopropyl Alcohol as an active ingredient. Prevantics Maxi Swabstick was launched by Prof Dspls in 2005.

Approval Date:

Prevantics Maxi Swabstick was approved by FDA for market use on 03 June, 2005.

Active Ingredient:

Prevantics Maxi Swabstick uses Chlorhexidine Gluconate; Isopropyl Alcohol as the active ingredient. Check out other Drugs and Companies using Chlorhexidine Gluconate; Isopropyl Alcohol ingredient

Dosage:

Prevantics Maxi Swabstick is available in swab form for topical use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
3.15%;70% (5.1ML) SWAB Over the counter TOPICAL